Acorda Therapeutics (NASDAQ:ACOR) Now Covered by StockNews.com

Analysts at StockNews.com began coverage on shares of Acorda Therapeutics (NASDAQ:ACORGet Free Report) in a report issued on Thursday. The firm set a “buy” rating on the biopharmaceutical company’s stock.

Acorda Therapeutics Price Performance

Shares of Acorda Therapeutics stock opened at $15.15 on Thursday. The company has a current ratio of 1.59, a quick ratio of 1.21 and a debt-to-equity ratio of 3.07. The stock has a market capitalization of $18.79 million, a price-to-earnings ratio of -0.89 and a beta of 1.44. Acorda Therapeutics has a 1-year low of $8.98 and a 1-year high of $24.20. The firm’s 50-day moving average price is $14.83 and its two-hundred day moving average price is $13.50.

Acorda Therapeutics (NASDAQ:ACORGet Free Report) last issued its quarterly earnings data on Monday, November 13th. The biopharmaceutical company reported ($7.16) earnings per share for the quarter. The firm had revenue of $27.72 million for the quarter. Acorda Therapeutics had a negative return on equity of 21.45% and a negative net margin of 14.35%.

Institutional Trading of Acorda Therapeutics

Several large investors have recently added to or reduced their stakes in ACOR. Renaissance Technologies LLC lifted its position in shares of Acorda Therapeutics by 27.4% during the second quarter. Renaissance Technologies LLC now owns 901,318 shares of the biopharmaceutical company’s stock worth $420,000 after purchasing an additional 194,100 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Acorda Therapeutics during the second quarter worth approximately $68,000. Millennium Management LLC lifted its position in shares of Acorda Therapeutics by 661.2% during the second quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company’s stock worth $145,000 after purchasing an additional 270,588 shares in the last quarter. Prudential Financial Inc. acquired a new position in shares of Acorda Therapeutics during the second quarter worth approximately $28,000. Finally, Geode Capital Management LLC lifted its position in shares of Acorda Therapeutics by 44.8% during the fourth quarter. Geode Capital Management LLC now owns 67,669 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 20,948 shares in the last quarter.

About Acorda Therapeutics

(Get Free Report)

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.

Further Reading

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.